Publications by authors named "A PLYM"
Article Synopsis
- The study aims to evaluate the effectiveness of the Stockholm3 test for prostate cancer detection in a diverse group of men, particularly those underrepresented in clinical trials.
- Conducted over several years across 17 sites, the study compared Stockholm3's performance against the traditional prostate-specific antigen (PSA) test, focusing on its ability to detect clinically significant cancer and reduce unnecessary biopsies.
- Findings revealed that Stockholm3 had similar sensitivity to PSA while offering significantly improved specificity, potentially lowering the number of benign biopsy results by up to 52% across various racial and ethnic groups.
Importance: Prostate cancer, a leading cause of cancer death among men, urgently requires new prevention strategies, which may involve targeting men with an underlying genetic susceptibility.
Objective: To explore differences in risk of early prostate cancer death among men with higher vs lower genetic risk to inform prevention efforts.
Design, Setting, And Participants: This cohort study used a combined analysis of genotyped men without prostate cancer at inclusion and with lifestyle data in 2 prospective cohort studies in Sweden and the US, the Malmö Diet and Cancer Study (MDCS) and the Health Professionals Follow-Up Study (HPFS), followed up from 1991 to 2019.
Background: This study aims to assess the impact of healthy lifestyle on prostate cancer (PCa) risk in a diverse population.
Methods: Data for 281,923 men from the Million Veteran Program (MVP), a nationwide, health system-based cohort study, were analyzed. Self-reported information at enrollment included smoking status, exercise, diet, family history of PCa, and race/ethnicity.
Background: The US government considers veterans to have been exposed to Agent Orange if they served in Vietnam while the carcinogen was in use, and these veterans are often deemed at high risk of prostate cancer (PCa). Here, we assess whether presumed Agent Orange exposure is independently associated with increased risk of any metastatic or fatal PCa in a diverse Veteran cohort still alive in the modern era (at least 2011), when accounting for race/ethnicity, family history, and genetic risk.
Patients And Methods: Participants in the Million Veteran Program (MVP; enrollment began in 2011) who were on active duty during the Vietnam War era (August 1964-April 1975) were included (n = 301,470).
Purpose: Family history and germline genetic risk single nucleotide polymorphisms (SNPs) have been separately shown to stratify lifetime risk of prostate cancer. Here, we evaluate the combined prognostic value of family history of prostate and other related cancers and germline risk SNPs among patients with favorable-risk prostate cancer.
Materials And Methods: A total of 1367 participants from the prospective Health Professionals Follow-up Study diagnosed with low- or favorable intermediate-risk prostate cancer from 1986 to 2017 underwent genome-wide SNP genotyping.